Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—Data from LIBERATE trial

Sismondi, P; Kimmig, Rainer; Kubista, E.; Biglia, Nicoletta; Egberts, Jan F M; Mulder, Roel; Planellas, Juan; Moggio, Giulia; Mol-Arts, Mirjam; Kenemans, P.

doi:10.1016/j.maturitas.2011.09.003

Cited by 43 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most important findings for breast cancer survivors are the results of the LIBERATE trial which was the first trial to study tibolone effects in a large breast cancer population compared with placebo [Kenemans et al 2009;Sismondi et al 2011]. The study showed that tibolone (2.5 mg) is effective in improving menopausal symptoms including vaginal dryness and enhanced QoL, but was associated with a significantly increased risk of breast cancer recurrence (HR: 1.40; CI 95%: 1.14-1.70) and is contraindicated after breast cancer, with the authors warning that any offlabel use incurs a proven risk [Sismondi et al 2011].…”

Section: Tibolonementioning

confidence: 99%

“…The study showed that tibolone (2.5 mg) is effective in improving menopausal symptoms including vaginal dryness and enhanced QoL, but was associated with a significantly increased risk of breast cancer recurrence (HR: 1.40; CI 95%: 1.14-1.70) and is contraindicated after breast cancer, with the authors warning that any offlabel use incurs a proven risk [Sismondi et al 2011]. This recommendation has been endorsed by the IMS [de Villiers et al 2013].…”

Section: Tibolonementioning

confidence: 99%

See 1 more Smart Citation

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

et al. 2017

View full text Add to dashboard Cite

There is increasing attention and concern about managing the adverse effects of adjuvant endocrine therapy for women with early breast cancer as the side effects of therapy influence compliance and can impair quality of life (QoL). Most side effects associated with tamoxifen (TAM) and aromatase inhibitors (AIs) are directly related to estrogen deprivation, and the symptoms are similar to those experienced during natural menopause but appear to be more severe than that seen in the general population. Prolonged estrogen deprivation may lead to atrophy of the vulva, vagina, lower urinary tract and supporting pelvic structures, resulting in a range of genitourinary symptoms that can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of QoL. The genitourinary side effects may be prevented, reduced and managed in most cases but this requires early recognition and appropriate treatment. We provide an overview of practical clinical approaches to understanding the pathophysiology and the management of genitourinary symptoms in postmenopausal women receiving adjuvant endocrine therapy for breast cancer.

show abstract

Section: Tibolonementioning

confidence: 99%

Section: Tibolonementioning

confidence: 99%

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The evidence of a reduced stimulatory effect on breast tissue compared with other HRT preparations meant that it was feasible to evaluate its safety in a randomized controlled trial in women with recently diagnosed breast cancer 24 . Quality of life was improved in the treatment group, but a higher rate of breast cancer recurrence was seen only in the women with ER+ disease.…”

Section: Tibolonementioning

confidence: 99%

Latest Evidence on Using Hormone Replacement Therapy in the Menopause

Akter¹,

Shirin²

2018

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Hormone replacement therapy (HRT) is the most effective therapy of menopausal symptoms for perimenopausal and menopausal women. When HRT is individually tailored women gain maximum advantages and the risk are minimized. There are different types of hormones with different doses and different routes of delivery exist. . The use of HRT is an individual decision which women can only make once she has been given correct information and advice from healthcare professionals. HRT should be recommended in women with premature ovarian insufficiency with advice to continue until the average age of menopause at 51.4 years. This review item promotes confidence in prescribing HRT in most symptomatic women. Prescribing HRT in women with relative contraindication where evidence is limited. Quality of life is priority. Multidisciplinary approach may be necessary and informed written consent documented.

show abstract

“…The current evidence does not support a specific psychosocial counselling intervention to improve sexual functioning and satisfaction. The evidence base for this recommendation consists of sixteen publications of moderate quality [31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] and four systematic reviews [14][15][16][17] . …”

Section: Overall Sexual Function and Satisfactionmentioning

confidence: 99%

“…In addition, eight other publications provide evidence of moderately high quality [38][39][40]44,45,[47][48][49] .…”

Section: Genital Symptomsmentioning

confidence: 99%

Interventions to Address Sexual Problems in People with Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—Data from LIBERATE trial

Cited by 43 publications

References 29 publications

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

Latest Evidence on Using Hormone Replacement Therapy in the Menopause

Interventions to Address Sexual Problems in People with Cancer

Contact Info

Product

Resources

About